Table 2.
IC50 | Mode of Inhibition | Substrate (PNPG, mM) | Remark | |||
---|---|---|---|---|---|---|
0.125 | 0.25 | 0.5 | 1 | |||
Glyceollin (μM) | Competitive | 16.57 ± 3.25 | 16.57 ± 0.15 | 19.11 ± 0.96 | 33.23 ± 3.97 | Synergistic |
Luteolin (μM) | Mixed | 18.63 ± 1.20 | 14.82 ± 0.01 | 15.35 ± 1.99 | 19.52 ± 1.59 | |
Glyceollin + Luteolin (μM) | 6.31 ± 0.59 *,# | 6.78 ± 0.18 *,# | 9.00 ± 0.40 *,# | 14.16 ± 0.35 * | ||
Glyceollin (μM) | Competitive | 16.57 ± 3.25 | 16.57 ± 0.15 | 19.11 ± 0.96 | 33.23 ± 3.97 | Non-synergistic |
Genistein (μM) | Noncompetitive | 40.47 ± 4.99 | 15.42 ± 0.33 | 12.00 ± 0.31 | 9.10 ± 0.61 | |
Glyceollin + Genistein (μM) | 32.47 ± 1.48 | 33.73 ± 1.51 | 20.67 ± 0.44 | 21.81 ± 0.58 | ||
Glyceollin (μM) | Competitive | 16.57 ± 3.25 | 16.57 ± 0.15 | 19.11 ± 0.96 | 33.23 ± 3.97 | Non-synergistic |
Daidzein (μM) | Uncompetitive | 59.16 ± 6.10 | 27.56 ± 2.93 | 23.19 ± 1.04 | 20.53 ± 1.82 | |
Glyceollin + Daidzein (μM) | 33.69 ± 0.65 | 22.78 ± 1.20 | 16.05 ± 0.51 | 19.04 ± 0.08 |
* p < 0.05: Combination treatment is significantly different from glyceollin alone. # p < 0.05: Combination treatment is significantly different from luteolin alone.